Apatinib for Inoperable Advanced Chondrosarcoma

Sponsor
Peking University People's Hospital
Study ID
NCT04260113
Status
Completed

Conditions

  • Efficacy
  • Toxicity, Drug

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.

Key Dates

Start date
Oct 1, 2019
Status verified
Jan 2021
Primary completion
Jan 1, 2020
Completion
Apr 1, 2020

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Arm

Primary Outcome Measure

progression-free survival [ Time Frame: 6 months ]

Related Studies